In the high-stakes world of modern medicine, finding a cure should be mathematically impossible. Researchers estimate there are 10^60 possible chemical compounds—or 10 to the 60th power, a number greater than that of stars in the observable universe—yet only a microscopic fraction will ever become viable medicines. Now, a convergence of Big Pharma and venture capital investment is betting billions that artificial intelligence can finally decode this infinite complexity.
One of the leaders of this movement is Isomorphic Labs, a drug-design company spun out of Google parent Alphabet. In a signal of the market’s appetite for AI-driven biotechnology, the company secured a massive $600 million Series A funding round in March 2025. The round was led by Joshua Kushner’s Thrive Capital, with participation from Google Ventures, validating a shift in investment philosophy: treating biology less like a game of chance and more like an engineering problem.
